Logo
GHRP 6 (5mg x 10 Vials) & Mod GRF 1 29 (CJC1295 no DAC) (5mg x 10 Vials)

GHRP 6 (5mg x 10 Vials) & Mod GRF 1 29 (CJC1295 no DAC) (5mg x 10 Vials)

Misc (Generics)

Research peptide bundle (laboratory chemical – not authorised medicinal product)
  • No MHRA marketing authorisation (PL number) is listed for this GHRP 6 / Mod GRF 1 29 (CJC1295 no DAC) research peptide bundle.
  • No CE or UKCA medical device marking is claimed, as the product is marketed as a chemical for research use rather than as a medical device.
  • Reference supplier legal notices state that all products are for research and development use only, not for human consumption, and that statements about the products have not been evaluated by the US Food and Drug Administration or equivalent authorities.
  • The seller of the dermafillerltd.uk product does not provide publicly accessible information on GMP certification, ISO standards or other quality system certifications specific to this peptide bundle.
Growth hormone\u2013releasing peptide (GHRP-6) and growth hormone\u2013releasing hormone analogue (Mod GRF 1-29 / CJC1295 no DAC) supplied as lyophilised powder vials

Description

This product is a research peptide bundle consisting of two separate lyophilised peptides: GHRP-6 (Growth Hormone Releasing Peptide-6) and Mod GRF 1-29 (also referred to as CJC1295 no DAC). The bundle contains 10 vials of GHRP-6, each with 5 mg of peptide, and 10 vials of Mod GRF 1-29, each with 5 mg of peptide, for a total of 20 vials. Peptide suppliers describe this combination as being provided in lyophilised (powder) form for maximum stability during shipping and storage, and label it for laboratory research use only, not for human consumption or therapeutic use.

Bnefits

  • Provides two complementary research peptides (GHRP-6 and Mod GRF 1-29 / CJC1295 no DAC) in a single bundle for experimental work.
  • Standardised vial content of 5 mg per vial for each peptide simplifies preparation of defined concentrations for laboratory experiments.
  • Total of 20 vials (10 of each peptide) offers multiple aliquots for repeated research runs.
  • Lyophilised (freeze-dried) peptide form improves stability for shipping and storage prior to reconstitution.
  • Commonly advertised by peptide suppliers with free shipping for this specific 5 mg x 10 / 5 mg x 10 bundle.
  • Explicitly labelled by major suppliers as intended for research and development use only, not for human consumption.

Indications

  • No approved therapeutic indications – supplied and labelled by peptide vendors as a research chemical bundle for laboratory use only.
  • Used in experimental research contexts investigating growth hormone–related signalling pathways and peptide pharmacology; such use is pre-clinical and not an authorised medical indication.
  • Explicitly not intended to diagnose, treat, cure or prevent any disease and not to be used as a drug, food additive or household chemical.

Composition

  • Bundle contents: 10 vials of GHRP-6, each containing 5 mg of lyophilised peptide powder; 10 vials of Mod GRF 1-29 (CJC1295 no DAC), each containing 5 mg of lyophilised peptide powder.
  • Physical form: lyophilised (freeze-dried) white or off-white peptide powder in sealed vials.
  • Total peptide content per bundle: 50 mg GHRP-6 and 50 mg Mod GRF 1-29, divided across 20 vials.
  • Specific amino-acid sequences, excipients, residual solvents, counter-ions and detailed impurity/purity specifications are not publicly listed for this particular product.
  • Suppliers describe the peptides in this bundle generically as high-purity research-grade materials without providing full certificates of analysis on the public product page.

Formulation

  • Dosage form: sterile lyophilised peptide powder in multi-use glass vials.
  • Strength: 5 mg per vial of GHRP-6; 5 mg per vial of Mod GRF 1-29 (CJC1295 no DAC).
  • Total quantity: 10 vials of GHRP-6 and 10 vials of Mod GRF 1-29 (20 vials in total).
  • Intended use: in-vitro or laboratory research; not formulated, labelled or approved for administration to humans or animals.
  • Peptide suppliers state that lyophilised peptides are shipped as powder and are typically reconstituted with bacteriostatic water by research users immediately before experimental use; specific reconstitution protocols for this product are not publicly listed.

Packaging

  • Combination package containing 20 individual vials: 10 vials of GHRP-6 (5 mg each) and 10 vials of Mod GRF 1-29 (5 mg each).
  • Each vial is supplied as sealed lyophilised powder in a small glass vial with stopper and cap (as shown on reference supplier images).
  • Vials are shipped in secondary protective cartons or boxes suitable for transport; detailed outer packaging specifications are not publicly listed.
  • No diluent (e.g. bacteriostatic water) is indicated as being included with the dermafillerltd.uk listing; public supplier pages for the same 5 mg x 10 / 5 mg x 10 combination likewise describe only the lyophilised vials.

Usage

  • No therapeutic or dosing instructions are provided, as this product is sold strictly for laboratory research use and is not intended for administration to humans or animals.
  • Major peptide suppliers for this 5 mg x 10 / 5 mg x 10 combination state that all products are for research and development use only and are not for human consumption of any kind.
  • Handling, reconstitution and experimental application must be carried out by qualified research personnel in appropriate laboratory facilities, following institutional safety procedures and any supplier technical documentation.
  • This product must not be used as a drug, food additive, cosmetic ingredient for direct human application, or in any other way that constitutes human or veterinary exposure.

Contraindications

  • No clinical contraindications are defined because the product is not authorised for therapeutic use.
  • Peptide suppliers specify that products are not for human consumption and must only be handled by qualified research personnel; any use outside of laboratory research would contravene the stated conditions of sale.

Adverse Effects

  • No formal adverse-effect profile is provided in publicly accessible information, as the product is not approved or marketed as a medicine.
  • Suppliers include general legal disclaimers that the products have not been evaluated by regulatory authorities (such as the US FDA), and that they are not intended to diagnose, treat, cure or prevent any disease.

Storage Conditions

  • Reference supplier storage guidance for this specific bundle states that products are manufactured using lyophilisation (freeze-drying) to ensure stability for shipping for up to approximately 3–4 months at ambient conditions.
  • Once peptides are reconstituted with bacteriostatic water, they should be stored in a refrigerator and are described as remaining stable for up to about 30 days.
  • Lyophilised vials should be kept cold and protected from light on receipt; short-term refrigeration is described as acceptable, with room-temperature storage for several weeks being generally adequate for lyophilised powder according to supplier guidance.
  • For longer-term storage (several months to years), reference supplier information recommends freezing at very low temperatures (e.g. −80 °C) to preserve peptide stability.
  • Specific storage instructions printed on the dermafillerltd.uk product packaging are not publicly listed and may vary; research users are expected to consult any accompanying documentation.

Duration

Not applicable \u2013 research peptide product with no authorised clinical use or defined treatment duration.

Onset

Not applicable \u2013 research peptide product; no approved therapeutic effects or onset profile for clinical use.

Browse more Research peptide bundle (laboratory chemical \u2013 not authorised medicinal product)

Top Treatments

Top Cities in the UK